A recent study, published in Epidemiology, analyzed trends in patients with systemic autoimmune rheumatic diseases (SARDs) from the first COVID-19 wave through the initial Omicron wave. Their goal was to investigate how trends of incidence and severity of COVID-19 in those with SARDs have changed over time.
Read More »New evidence suggests that an autoimmune response to the SARS-CoV-2 virus is responsible for neurological disorders in some COVID-19 patients. A 2022 review by Dr. Daniela Latorre from the Institute of Microbiology in Zurich, Switzerland, explains the “current knowledge of immune responses occurring in Neuro-COVID patients” and the potential mechanisms for developing neurological complications alongside SARS-CoV-2 infection.
Read More »A 2022 study by the University Medical Center Hamburg-Eppendorf in Germany investigated the effect of the third COVID-19 vaccination on patients of autoimmune hepatitis (AIH). The level of anti-SARS-CoV-2 antibodies was measured in the blood of 81 autoimmune hepatitis patients.
Read More »A study published in the Journal of Autoimmunity evaluated the immune response of Pfizer and Moderna’s mRNA COVID-19 vaccines in participants with autoimmune systemic diseases. In total, serum samples from 244 AD patients were collected 2-4 weeks and six months after their first vaccine cycle, and 2-4 weeks following their booster dose; 502 people from the general population were used as a control group.
Read More »